Background: Systemic lupus erythematosus (SLE) is systemic autoimmune disease with variable clinical presentations. Lupus nephritis (LN) is type of glomerulonephritis that affect SLE patients and considers one of the most serious organ manifestations of SLE. SLE patients may develop LN within 5 years of SLE diagnosis and, in many cases, LN is the presenting manifestation. Objective: Our study aimed to determine the value of suPAR levels in lupus nephritis patients and its correlation with renal biobsy. Patients and Methods: This study was conducted in the Outpatient Clinics of Internal Medicine of Zagazig University Hospitals, Egypt, on 90 subjects both females and males. These participants were divided into three groups: Group (A): Comprised 30 SLE patients according to the 2019 EULAR/ACR classification criteria for SLE, without LN. Group (B): Included 30 SLE with LN patients. Group (C): Involved 30 healthy individuals were chosen with age and sex matching previous groups. Soluble urokinase plasminogen activator receptor (suPAR) was measured for all groups. Results: Our study revealed there was statistically significant increase suPAR in LN and SLE patients compared to control participants and also in LN patients compared to SLE patients. There was a statistically significant positive correlation between suPAR and LN class in LN patients as suPAR level increased with increased degree of LN class. Our results show suPAR had sensitivity 93.3%, specificity 90% and accuracy 91.7% in diagnosis of LN. Conclusion: Circulating suPAR can be considered a good marker to identify high risky patients with disease progression especially LN.